GlassScriptPhysician profile
Lori A Black
NPI 1932799244
$9,629.17
in general payments reported to CMS, 2019-2025
59 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $960 · 2022: $1,877 · 2023: $2,072 · 2024: $2,521 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,347 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,347.01 |
| Education | $445.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $774.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $712.25 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $577.00 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $502.72 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $497.95 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $495.05 | 2021-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Janssen Biotech, INC. | $450.24 | 2021-2025 | Erleada, Balversa, Tecvayli |
| Incyte Corporation | $376.54 | 2021-2025 | Monjuvi, Jakafi |
| Amgen INC. | $362.38 | 2021-2023 | Lumakras, Xgeva, Nplate |
| Genzyme Corporation | $332.53 | 2021-2025 | |
| Puma Biotechnology, INC. | $263.34 | 2021-2025 | Nerlynx |
| Lilly USA, LLC | $254.07 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $241.45 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $232.86 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Sumitomo Pharma America, INC. | $230.76 | 2023-2025 | Orgovyx |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $166.65 | 2023-2025 | Libtayo |
| Pfizer INC. | $164.25 | 2024-2025 | |
| Seagen INC. | $161.79 | 2022-2023 | Padcev, Tukysa |
| Beigene USA, INC. | $161.56 | 2021-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $154.29 | 2021-2025 | Onivyde, Tazverik |
| Exelixis INC. | $154.04 | 2021-2025 | Cabometyx |
| Eisai INC. | $153.74 | 2021-2025 | |
| Celgene Corporation | $141.89 | 2022-2024 | Pomalyst, Reblozyl, Opdualag |
| Astellas Pharma US INC | $129.32 | 2024-2025 | Vyloy |
| Emd Serono, INC. | $125.74 | 2023-2024 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $119.42 | 2021-2025 | |
| Iovance Biotherapeutics, INC. | $107.81 | 2025 | Amtagvi |
| Genentech USA, INC. | $102.84 | 2021-2024 | Phesgo, Tecentriq, Polivy |
| Boston Scientific Corporation | $93.68 | 2022-2025 | Eluvia, Cds - Mct/Cem Monitoring |
| Pharmacosmos Therapeutics INC. | $93.27 | 2021-2024 | Monoferric, Cosela |
| Sobi, INC | $90.99 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.23 | 2023-2025 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $86.95 | 2022-2025 | Fotivda |
| Adc Therapeutics America, INC. | $83.18 | 2022-2023 | |
| Beone Medicines USA, INC. | $79.79 | 2025 | Brukinsa, Tevimbra |
| Dova Pharmaceuticals | $71.49 | 2021 | |
| Kyowa Kirin, INC. | $69.19 | 2021-2025 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $58.42 | 2021-2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $56.21 | 2021-2023 | Imbruvica |
| Tersera Therapeutics LLC | $56.20 | 2021-2023 | Zoladex |
| Alnylam Pharmaceuticals INC. | $50.51 | 2022-2025 | Amvuttra |
| Caris Mpi, INC. | $48.39 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $44.74 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| G1 Therapeutics, INC. | $44.30 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $42.58 | 2023 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $41.46 | 2022-2023 | Opdivo |
| Acrotech Biopharma INC. | $32.71 | 2024 | Beleodaq |
| Servier Pharmaceuticals LLC | $31.75 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $30.29 | 2023 | Empaveli |
| Dendreon Pharmaceuticals LLC | $29.96 | 2022 | |
| Morphosys, US INC. | $25.60 | 2021-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $20.16 | 2022-2024 | Rezlidhia, Tavalisse |
| Tempus Ai, INC | $20.12 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.72 | 2025 | |
| Novocure INC. | $17.73 | 2023 | Optune |
| Pharmaessentia USA Corporation | $16.43 | 2024 | Besremi |
| Janssen Pharmaceuticals, INC | $14.18 | 2021 | |
| Epizyme, INC. | $11.60 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.